MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 535756 | Name: BM 34

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BM 34 is a bioactive chemical.

Chemical Structure

BM 34
BM 34
CAS#151162-46-8

Theoretical Analysis

MedKoo Cat#: 535756

Name: BM 34

CAS#: 151162-46-8

Chemical Formula: C20H32N4O2S2

Exact Mass: 424.1967

Molecular Weight: 424.62

Elemental Analysis: C, 56.57; H, 7.60; N, 13.19; O, 7.54; S, 15.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
BM 34; BM-34; BM34
IUPAC/Chemical Name
3-Pyridinesulfonamide, N-((cyclohexylamino)thioxomethyl)-4-(cyclooctylamino)-
InChi Key
WFSLNOMOIPDWSY-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H32N4O2S2/c25-28(26,24-20(27)23-17-11-7-4-8-12-17)19-15-21-14-13-18(19)22-16-9-5-2-1-3-6-10-16/h13-17H,1-12H2,(H,21,22)(H2,23,24,27)
SMILES Code
O=S(C1=C(NC2CCCCCCC2)C=CN=C1)(NC(NC3CCCCC3)=S)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 424.62 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Eapen M, Logan BR, Horowitz MM, Zhong X, Perales MA, Lee SJ, Rocha V, Soiffer RJ, Champlin RE. Bone marrow or peripheral blood for reduced-intensity conditioning unrelated donor transplantation. J Clin Oncol. 2015 Feb 1;33(4):364-9. doi: 10.1200/JCO.2014.57.2446. Epub 2014 Dec 22. PMID: 25534391; PMCID: PMC4302216. 2: Muramoto GG, Russell JL, Safi R, Salter AB, Himburg HA, Daher P, Meadows SK, Doan P, Storms RW, Chao NJ, McDonnell DP, Chute JP. Inhibition of aldehyde dehydrogenase expands hematopoietic stem cells with radioprotective capacity. Stem Cells. 2010 Mar 31;28(3):523-34. doi: 10.1002/stem.299. PMID: 20054864; PMCID: PMC3909217. 3: Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial of Graft- versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May;21(5):906-12. doi: 10.1016/j.bbmt.2015.01.026. Epub 2015 Feb 7. PMID: 25667989; PMCID: PMC4825327. 4: Masereel B, Lambert DM, Dogné JM, Poupaert JH, Delarge J. Anticonvulsant activity of pyrid-3-yl-sulfonyl ureas and thioureas. Epilepsia. 1997 Mar;38(3):334-7. doi: 10.1111/j.1528-1157.1997.tb01125.x. PMID: 9070596. 5: Masereel B, Dogné JM, Damas J, Nuhrich A, Varache-Lembège M, Fontaine J, Pochet L, Somers F, de Tullio P, Pirotte B, Delarge J. Pharmacomodulation of torasemide led to original diuretic, neuroprotective, anticonvulsant and antithrombotic drugs. J Pharm Belg. 1997 Jul-Aug;52(4):157-8. PMID: 9316342. 6: Cho SH, Chung IJ, Lee JJ, Park ML, Kim HJ. Comparison of CD34+ subsets and clonogenicity in human bone marrow, granulocyte colony-stimulating factor- mobilized peripheral blood, and cord blood. J Korean Med Sci. 1999 Oct;14(5):520-5. doi: 10.3346/jkms.1999.14.5.520. PMID: 10576147; PMCID: PMC3054470. 7: Masereel B, Wouters J, Pochet L, Lambert D. Design, synthesis, and anticonvulsant activity of 1-(pyrid-3-ylsulfonamido)-2-nitroethylenes. J Med Chem. 1998 Aug 13;41(17):3239-44. doi: 10.1021/jm981022n. PMID: 9703469. 8: Ringdahl B, Markowicz ME. Muscarinic and antimuscarinic activity of acetamides related to oxotremorine in the guinea pig urinary bladder. J Pharmacol Exp Ther. 1987 Mar;240(3):789-94. PMID: 3559974. 9: Roberts AW, Metcalf D. Noncycling state of peripheral blood progenitor cells mobilized by granulocyte colony-stimulating factor and other cytokines. Blood. 1995 Aug 15;86(4):1600-5. PMID: 7543309.